These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 1422962

  • 1. Rectal salmon calcitonin for the treatment of postmenopausal osteoporosis.
    Overgaard K, Hansen MA, Dirksen KL, Christiansen C.
    Calcif Tissue Int; 1992 Sep; 51(3):184-8. PubMed ID: 1422962
    [Abstract] [Full Text] [Related]

  • 2. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 3. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
    Overgaard K, Hansen MA, Nielsen VA, Riis BJ, Christiansen C.
    Am J Med; 1990 Jul; 89(1):1-6. PubMed ID: 2152594
    [Abstract] [Full Text] [Related]

  • 4. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.
    Nielsen NM, von der Recke P, Hansen MA, Overgaard K, Christiansen C.
    Calcif Tissue Int; 1994 Jul; 55(1):8-11. PubMed ID: 7922794
    [Abstract] [Full Text] [Related]

  • 5. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [Abstract] [Full Text] [Related]

  • 6. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P.
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis.
    Kollerup G, Hermann AP, Brixen K, Lindblad BE, Mosekilde L, Sørensen OH.
    Calcif Tissue Int; 1994 Jan; 54(1):12-5. PubMed ID: 8118746
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
    Ofluoglu D, Karadag-Saygi E, Canbulat C, Gunduz OH, Kul-Panza E, Akyuz G.
    Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
    [Abstract] [Full Text] [Related]

  • 13. Comparison of vitamin D metabolism in early healthy and late osteoporotic postmenopausal women.
    Hartwell D, Riis BJ, Christiansen C.
    Calcif Tissue Int; 1990 Dec; 47(6):332-7. PubMed ID: 2292078
    [Abstract] [Full Text] [Related]

  • 14. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.
    Overgaard K.
    Calcif Tissue Int; 1994 Aug; 55(2):82-6. PubMed ID: 7953984
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
    Tankó LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C.
    J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
    [Abstract] [Full Text] [Related]

  • 16. Long-term treatment of established osteoporosis with intranasal calcitonin.
    Overgaard K, Christiansen C.
    Calcif Tissue Int; 1991 Sep; 49 Suppl():S60-3. PubMed ID: 1933601
    [Abstract] [Full Text] [Related]

  • 17. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
    Thamsborg G, Jensen JE, Kollerup G, Hauge EM, Melsen F, Sorensen OH.
    Bone; 1996 Feb; 18(2):207-12. PubMed ID: 8833216
    [Abstract] [Full Text] [Related]

  • 18. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients.
    Hodsman AB, Fraher LJ.
    Bone Miner; 1990 May; 9(2):137-52. PubMed ID: 2161692
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Nasal calcitonin for treatment of established osteoporosis.
    Overgaard K, Riis BJ, Christiansen C, Pødenphant J, Johansen JS.
    Clin Endocrinol (Oxf); 1989 Apr; 30(4):435-42. PubMed ID: 2688995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.